- Home
- RSF vs ACRV Comparison
RSF vs ACRV Comparison
Compare RSF & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RSF | ACRV |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | 78 |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 56.5M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | RSF | ACRV |
|---|---|---|
| Price | $14.49 | $1.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 11.8K | ★ 3.6M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.81 | $1.05 |
| 52 Week High | $16.23 | $8.00 |
Technical Indicators
Market Signals| Indicator | RSF | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 42.37 |
| Support Level | $14.46 | $1.57 |
| Resistance Level | $14.60 | $2.01 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 49.98 | 42.74 |
Price Performance
Historical ComparisonAbout RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.